Skip to main content
Top
Published in: Rheumatology International 7/2019

01-07-2019 | Echocardiography | Observational Research

Epicardial adipose tissue thickness in systemic sclerosis patients without overt cardiac disease

Authors: Duygu Temiz Karadag, Tayfun Sahin, Senem Tekeoglu, Ozlem Ozdemir Isik, Ayten Yazici, Ayse Cefle

Published in: Rheumatology International | Issue 7/2019

Login to get access

Abstract

Systemic sclerosis is associated with an increased prevalence/incidence of coronary artery disease. The aim of this study was to investigate epicardial adipose tissue (EAT) thickness which may contribute to cardio-metabolic risk in systemic sclerosis (SSc) patients without overt cardiac disease. EAT thickness was measured by transthoracic conventional Doppler echocardiography and compared in SSc patients (n = 47) and age- and sex-matched healthy controls (n = 36). The relationships between EAT thickness and markers of cardio-metabolic risk in SSc were examined. EAT thickness was significantly greater in patients with SSc compared to healthy controls (6 [7–5] vs 5 [6.75–3.25], p = 0.041). Compared to controls, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), leukocyte, neutrophil, B-type natriuretic protein (BNP), fasting plasma insulin and HOMA-IR were elevated (18 [31–10] vs 8.5 [18–4], p < 0.001; 0.4 [0.67–0.18] vs 0.21 [0.48–0.09], p = 0.012; 7510 [8731–5990] vs 6435 [7360–5195], p = 0.002; 4350 [5440–3570] vs 3390 [4168–2903], p < 0.001; 111 [185–74] vs 70 [127–70], p = 0.010; 6.7 [10.5–4.7] vs 4.7 [6.8–4.1], p = 0.008; 1.7 [2.6–1] vs 1.1 [1.7–0.9], p = 0.015, respectively). The total and low-density lipoprotein (LDL)-cholesterol were decreased in SSc patients (197 ± 45 vs 284 ± 36, p = 0.005; 118 [148–84] vs 140 [180–115], p = 0.003, respectively). In patients with SSc, the EAT thickness correlated positively with age, ESR, CRP, insulin, hemoglobin A1c and total and LDL-cholesterol (r = 0.574, p < 0.001; r = 0.352, p = 0.015; r = 0.334, p = 0.022; r = 0.290, p = 0.048; r = 0.317, p = 0.030; r = 0.396, p = 0.006 and r = 0.349, p = 0.016, respectively). Our study confirms that EAT thickness is greater in SSc patients compared to healthy controls using echocardiographic measurements. The results of our study suggest that EAT thickness is a candidate for atherosclerotic risk assessment in SSc.
Literature
2.
go back to reference Kahan A, Allanore Y (2006) Primary myocardial involvement in systemic sclerosis. Rheumatol (Oxf) 45(Suppl. 4):7 Kahan A, Allanore Y (2006) Primary myocardial involvement in systemic sclerosis. Rheumatol (Oxf) 45(Suppl. 4):7
6.
go back to reference Szucs G, Tímár O, Szekanecz Z, Dér H, Kerekes G, Szamosi S, Shoenfeld Y, Szegedi G, Soltész P (2007) Endothelial dysfunction precedes atherosclerosis in systemic sclerosis—relevance for prevention of vascular complications. Rheumatol (Oxf) 46:759–762CrossRef Szucs G, Tímár O, Szekanecz Z, Dér H, Kerekes G, Szamosi S, Shoenfeld Y, Szegedi G, Soltész P (2007) Endothelial dysfunction precedes atherosclerosis in systemic sclerosis—relevance for prevention of vascular complications. Rheumatol (Oxf) 46:759–762CrossRef
7.
go back to reference Blagojevic J, Matucci Cerinic M (2007) Macrovascular involvement in systemic sclerosis: comorbidity or accelerated atherosclerosis? Curr Rheumatol 9:181–182CrossRef Blagojevic J, Matucci Cerinic M (2007) Macrovascular involvement in systemic sclerosis: comorbidity or accelerated atherosclerosis? Curr Rheumatol 9:181–182CrossRef
10.
go back to reference Szentpetery A, Healy GM, Brady D, Haroon M, Gallagher P, Redmond CE, Fleming H, Duignan J, Dodd JD, FitzGerald O (2018) Higher coronary plaque burden in psoriatic arthritis is independent of metabolic syndrome and associated with underlying disease severity. Arthritis Rheumatol 70:396–407. https://doi.org/10.1002/art.40389 CrossRefPubMed Szentpetery A, Healy GM, Brady D, Haroon M, Gallagher P, Redmond CE, Fleming H, Duignan J, Dodd JD, FitzGerald O (2018) Higher coronary plaque burden in psoriatic arthritis is independent of metabolic syndrome and associated with underlying disease severity. Arthritis Rheumatol 70:396–407. https://​doi.​org/​10.​1002/​art.​40389 CrossRefPubMed
11.
go back to reference Matloch Z, Kotulak T, Haluzık M (2016) The role of epicardial adipose tissue in heart disease. Physiol Res 65:23–32PubMed Matloch Z, Kotulak T, Haluzık M (2016) The role of epicardial adipose tissue in heart disease. Physiol Res 65:23–32PubMed
12.
go back to reference Parisi V, Rengo G, Pagano G, D’Esposito V, Passaretti F, Caruso A, Grimaldi MG, Lonobile T, Baldascino F, De Bellis A, Formisano P, Ferrara N, Leosco D (2015) Epicardial adipose tissue has an increased thickness and is a source of inflammatory mediators in patients with calcific aortic stenosis. Int J Cardiol 186:167–169. https://doi.org/10.1016/j.ijcard.2015.03.201 CrossRefPubMed Parisi V, Rengo G, Pagano G, D’Esposito V, Passaretti F, Caruso A, Grimaldi MG, Lonobile T, Baldascino F, De Bellis A, Formisano P, Ferrara N, Leosco D (2015) Epicardial adipose tissue has an increased thickness and is a source of inflammatory mediators in patients with calcific aortic stenosis. Int J Cardiol 186:167–169. https://​doi.​org/​10.​1016/​j.​ijcard.​2015.​03.​201 CrossRefPubMed
15.
go back to reference Iacobellis G, Assael F, Ribaudo MC, Zappaterreno A, Alessi G, Di Mario U, Leonetti F (2003) Epicardial fat from echocardiography: a new method for visceral adipose tissue prediction. Obes Res 11:304–310CrossRefPubMed Iacobellis G, Assael F, Ribaudo MC, Zappaterreno A, Alessi G, Di Mario U, Leonetti F (2003) Epicardial fat from echocardiography: a new method for visceral adipose tissue prediction. Obes Res 11:304–310CrossRefPubMed
17.
go back to reference LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, Rowell N, Wollheim F (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15:202–205PubMed LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, Rowell N, Wollheim F (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15:202–205PubMed
18.
go back to reference Clements P, Lachenbruch P, Siebold J et al (1995) Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol. 22:1281–1285PubMed Clements P, Lachenbruch P, Siebold J et al (1995) Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol. 22:1281–1285PubMed
19.
go back to reference Medsger TA Jr, Bombardieri S, Czirjak L, Scorza R, Della Rossa A, Bencivelli W (2003) Assessment of disease severity and prognosis. Clin Exp Rheumatol 21:42–46 Medsger TA Jr, Bombardieri S, Czirjak L, Scorza R, Della Rossa A, Bencivelli W (2003) Assessment of disease severity and prognosis. Clin Exp Rheumatol 21:42–46
20.
go back to reference Valentini G, Iudici M, Walker UA, Jaeger VK, Baron M, Carreira P (2017) The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index. Ann Rheum Dis. 76:270–276CrossRefPubMed Valentini G, Iudici M, Walker UA, Jaeger VK, Baron M, Carreira P (2017) The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index. Ann Rheum Dis. 76:270–276CrossRefPubMed
21.
go back to reference Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ, National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, National High Blood Pressure Education Program Coordinating Committee (2003) The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289:2560–272CrossRefPubMed Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ, National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, National High Blood Pressure Education Program Coordinating Committee (2003) The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289:2560–272CrossRefPubMed
22.
go back to reference Hsu VM, Moreyra AE, Wilson AC, Shinnar M, Shindler DM, Wilson JE, Desai A, Seibold JR (2008) Assessment of pulmonary arterial hypertension in patients with systemic sclerosis: comparison of noninvasive tests with results of right-heart catheterization. J Rheumatol 35:458–465PubMed Hsu VM, Moreyra AE, Wilson AC, Shinnar M, Shindler DM, Wilson JE, Desai A, Seibold JR (2008) Assessment of pulmonary arterial hypertension in patients with systemic sclerosis: comparison of noninvasive tests with results of right-heart catheterization. J Rheumatol 35:458–465PubMed
23.
go back to reference Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419CrossRefPubMed Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419CrossRefPubMed
24.
go back to reference WHO (1995) Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser 854:1–452 WHO (1995) Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser 854:1–452
25.
go back to reference Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285:2486–2497. https://doi.org/10.1001/jama.285.19.2486 CrossRef Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285:2486–2497. https://​doi.​org/​10.​1001/​jama.​285.​19.​2486 CrossRef
26.
go back to reference Lang RM, Bierig M, Devereux RB et al (2005) Chamber Quantification Writing Group; American Society of Echocardiography’s Guidelines and Standards Committee; European Association of Echocardiography. Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 18:1440–1463CrossRefPubMed Lang RM, Bierig M, Devereux RB et al (2005) Chamber Quantification Writing Group; American Society of Echocardiography’s Guidelines and Standards Committee; European Association of Echocardiography. Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 18:1440–1463CrossRefPubMed
32.
go back to reference Singh N, Singh H, Khanijoun HK, Iacobellis G (2007) Echocardiographic assessment of epicardial adipose tissue–a marker of visceral adiposity. McGill Med J 10:26–30 Singh N, Singh H, Khanijoun HK, Iacobellis G (2007) Echocardiographic assessment of epicardial adipose tissue–a marker of visceral adiposity. McGill Med J 10:26–30
33.
go back to reference Mazurek T, Zhang L, Zalewski A, Mannion JD, Diehl JT, Arafat H, Sarov-Blat L, O’Brien S, Keiper EA, Johnson AG, Martin J, Goldstein BJ, Shi Y (2003) Human epicardial adipose tissue is a source of inflammatory mediators. Circulation 108(20):2460–2466CrossRefPubMed Mazurek T, Zhang L, Zalewski A, Mannion JD, Diehl JT, Arafat H, Sarov-Blat L, O’Brien S, Keiper EA, Johnson AG, Martin J, Goldstein BJ, Shi Y (2003) Human epicardial adipose tissue is a source of inflammatory mediators. Circulation 108(20):2460–2466CrossRefPubMed
34.
go back to reference Medsger TA Jr, Silman AJ, Steen VD et al (1999) A disease severity scale for systemic sclerosis: development and testing. J Rheumatol 26:2159–2167PubMed Medsger TA Jr, Silman AJ, Steen VD et al (1999) A disease severity scale for systemic sclerosis: development and testing. J Rheumatol 26:2159–2167PubMed
35.
36.
go back to reference Iacobellis G, Ribaudo MC, Assael F, Vecci E, Tiberti C, Zappaterreno A, Di Mario U, Leonetti F (2003) Echocardiographic epicardial adipose tissue is related to anthropometric and clinical parameters of metabolic syndrome: a new indicator of cardiovascular risk. J Clin Endocrinol Metab 88:5163–5168CrossRefPubMed Iacobellis G, Ribaudo MC, Assael F, Vecci E, Tiberti C, Zappaterreno A, Di Mario U, Leonetti F (2003) Echocardiographic epicardial adipose tissue is related to anthropometric and clinical parameters of metabolic syndrome: a new indicator of cardiovascular risk. J Clin Endocrinol Metab 88:5163–5168CrossRefPubMed
39.
go back to reference Flüchter S, Haghi D, Dinter D, Heberlein W, Kühl HP, Neff W, Sueselbeck T, Borggrefe M, Papavassiliu T (2007) Volumetric assessment of epicardial adipose tissue with cardiovascular magnetic resonance imaging. Obesity 15:870–878CrossRefPubMed Flüchter S, Haghi D, Dinter D, Heberlein W, Kühl HP, Neff W, Sueselbeck T, Borggrefe M, Papavassiliu T (2007) Volumetric assessment of epicardial adipose tissue with cardiovascular magnetic resonance imaging. Obesity 15:870–878CrossRefPubMed
40.
go back to reference Abbara S, Desai JC, Cury RC, Butler J, Nieman K, Reddy V (2005) Mapping epicardial fat with multi-detector computed tomography to facilitate percutaneous transepicardial arrhythmia ablation. Eur J Radiol 57:417–422CrossRef Abbara S, Desai JC, Cury RC, Butler J, Nieman K, Reddy V (2005) Mapping epicardial fat with multi-detector computed tomography to facilitate percutaneous transepicardial arrhythmia ablation. Eur J Radiol 57:417–422CrossRef
41.
go back to reference Yiu KH, Schouffoer AA, Marsan NA, Ninaber MK, Stolk J, Vlieland TV, Scherptong RW, Delgado V, Holman ER, Tse HF, Huizinga TW, Bax JJ, Schuerwegh AJ (2011) Left ventricular dysfunction assessed by speckle tracking strain analysis in patients with systemic sclerosis: relationship to functional capacity and ventricular arrhythmias. Arthrit Rheumat 63:3969–3978. https://doi.org/10.1002/art.30614 CrossRef Yiu KH, Schouffoer AA, Marsan NA, Ninaber MK, Stolk J, Vlieland TV, Scherptong RW, Delgado V, Holman ER, Tse HF, Huizinga TW, Bax JJ, Schuerwegh AJ (2011) Left ventricular dysfunction assessed by speckle tracking strain analysis in patients with systemic sclerosis: relationship to functional capacity and ventricular arrhythmias. Arthrit Rheumat 63:3969–3978. https://​doi.​org/​10.​1002/​art.​30614 CrossRef
Metadata
Title
Epicardial adipose tissue thickness in systemic sclerosis patients without overt cardiac disease
Authors
Duygu Temiz Karadag
Tayfun Sahin
Senem Tekeoglu
Ozlem Ozdemir Isik
Ayten Yazici
Ayse Cefle
Publication date
01-07-2019
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 7/2019
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-019-04306-8

Other articles of this Issue 7/2019

Rheumatology International 7/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.